Hill-Rom Holdings, Inc. (NYSE:HRC) – Northcoast Research lowered their Q1 2020 earnings per share estimates for Hill-Rom in a research note issued on Tuesday, November 5th. Northcoast Research analyst D. Keiser now expects that the medical technology company will earn $1.08 per share for the quarter, down from their previous estimate of $1.09. Northcoast Research also issued estimates for Hill-Rom’s Q2 2020 earnings at $1.19 EPS, Q3 2020 earnings at $1.34 EPS and FY2020 earnings at $5.54 EPS.

Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, November 1st. The medical technology company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.04. Hill-Rom had a return on equity of 21.67% and a net margin of 5.24%. The company had revenue of $782.80 million for the quarter, compared to analyst estimates of $759.14 million. During the same quarter in the previous year, the firm earned $1.63 earnings per share. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year.

Other equities research analysts have also issued research reports about the company. Morgan Stanley boosted their price target on Hill-Rom from $108.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Monday. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Barclays boosted their price target on Hill-Rom from $108.00 to $116.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $125.00 price target on shares of Hill-Rom in a research note on Tuesday, August 6th. Finally, UBS Group boosted their price target on Hill-Rom from $122.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Hill-Rom presently has an average rating of “Buy” and an average target price of $118.67.

HRC traded up $0.68 on Friday, hitting $103.97. The company had a trading volume of 288,404 shares, compared to its average volume of 451,472. The stock has a fifty day moving average price of $102.73 and a 200-day moving average price of $103.02. Hill-Rom has a 12-month low of $81.85 and a 12-month high of $111.63. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.10 and a current ratio of 1.31. The stock has a market capitalization of $6.90 billion, a price-to-earnings ratio of 20.47, a P/E/G ratio of 1.88 and a beta of 0.83.

In other news, SVP Paul Sherwood Johnson sold 6,470 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $104.26, for a total transaction of $674,562.20. Following the sale, the senior vice president now owns 8,215 shares in the company, valued at $856,495.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.73% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Hill-Rom by 4.9% during the second quarter. BlackRock Inc. now owns 6,649,313 shares of the medical technology company’s stock worth $695,650,000 after purchasing an additional 307,825 shares during the period. Vanguard Group Inc. lifted its holdings in Hill-Rom by 2.6% in the second quarter. Vanguard Group Inc. now owns 6,322,476 shares of the medical technology company’s stock valued at $661,458,000 after acquiring an additional 163,177 shares during the period. Invesco Ltd. lifted its holdings in Hill-Rom by 3.9% in the second quarter. Invesco Ltd. now owns 1,120,793 shares of the medical technology company’s stock valued at $117,257,000 after acquiring an additional 42,163 shares during the period. Bank of New York Mellon Corp lifted its holdings in Hill-Rom by 3.9% in the second quarter. Bank of New York Mellon Corp now owns 1,120,643 shares of the medical technology company’s stock valued at $117,242,000 after acquiring an additional 41,997 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Hill-Rom by 18.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 911,289 shares of the medical technology company’s stock valued at $95,340,000 after acquiring an additional 141,657 shares during the period. Institutional investors and hedge funds own 82.61% of the company’s stock.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Read More: How to Track your Portfolio in Google Finance

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.